Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death

Cancer Research

Volumn 56, Issue 18, 1996, Pages 4213-4218

  Demartis, Anna ^a   Bernassola, Francesca ^b   Savino, Rocco ^a   Melino, Gennaro ^b,c   Ciliberto, Gennaro ^a  

^a IRBM   (Italy)

^b Biochemistry Lab   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANTIGENS, CD; APOPTOSIS; CELL LINE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; MULTIPLE MYELOMA; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0029812490     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Van Snick, J. Interleukin-6: an overview. Annu. Rev. Immunol., 8 253-278, 1990.
2. Kishimoto, T , Akira, S., Narazaki, M , and Taga, T. Blood, 86 1243-1254, 1995.
3. Hirano, T., Akira, S., Taga, T., and Kishimoto, T Biological and clinical aspects of interleukin 6. Immunol. Today, 11: 443-449, 1990.
4. Poli, V., Balena, R , Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G , Rodan, G. A , and Costantini, F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J., 13: 1189-1196, 1994
5. Hilbert, D M , Kopf, M , Mock, B A., Köhler, G , and Rodikoff, S. Interleukin 6 is essential for in vivo development of B lineage neoplasm. J. Exp. Med., 182: 243-248, 1995
6. Bataille, R., Jourdan, M., Zhang, X. G , and Klein, B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease seventy in plasma cell dyscrasias. J. Clin. Invest., 84: 2008-2011, 1989.
7. Ludwig, H , Nachbaur, D. M., Fritz, E., Krainer, M., and Huber, H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood, 77: 2794-2795, 1991.
8. Pelliniemi, T. T., Irjala, K , Mattila, K , Pulkki, K., Rajamaki, A., Tienhaara, A., Laakso, M., and Lahtinen, R. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma Blood, 85. 765-771, 1995.
9. Klein, B , Zhang, X. G , Jourdan, M., Content, J , Houssiau, F., Aarden, L., Piechaczyk, M.. and Bataille, R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73: 517-526, 1989.
10. Klein, B., Wijdenes, J., Zhang, X-G., Jourdan, M., Boiron, J-M , Brochier, J., Liautard, J , Merlin, M , Clement, C., Mourel-Fournier, B., Zhao-Liang, L , Mannoni, P, Sany, J , and Bataille, R. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78 1198-1204, 1991.
11. Bataille, R., Barlogie, B., Lu, Z. Y , Rossi, J-F, Lavabre-Bertrand, T , Beck, T., Wijdenes, J , Brochier, J., and Klein, B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685-691, 1995
12. Lu, Z. Y., Brailly, J., Wijdenes, J., Bataille, R , Rossi, J. F., and Klein, B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood, 86: 3123-3131, 1995.
13. Savino, R , Lahm, A., Salvati, A. L , Ciapponi, L , Sporeno, E., Altamura, S , Paonessa, G., Toniatti, C., and Ciliberto, G. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J., 13: 1357-1367, 1994
14. Leebeek, F. W G , Karyya, K., Scwabe, M., and Fowlkes, D. M. Identification of a receptor binding site in the carboxyl terminus of human interleukin-6. J Biol. Chem., 267: 14832-14838, 1992.
15. Savino, R., Lahm, A., Giorgio, M , Cabibbo, A., Tramontano, A., and Ciliberto, G Saturation mutagenesis of the human interleukin 6 receptor-binding site: implication for its three-dimensional structure. Proc. Natl. Acad. Sci. USA, 90: 4067-4071, 1993.
16. Toniatti, C., Cabibbo, A., Sporeno, E , Salvati, A. L , Cerretani, M., Serafini, S , Lahm, A., Cortese, R., and Ciliberto, G. Engineering human IL-6 to obtain variants with strongly enhanced bioactivity. EMBO J., 15: 2726-2737, 1996.
17. Paonessa, G , Graziani, R., De Serio, A., Savino, R., Ciapponi, L., Lahm, A., Salvati, A. L., Toniatti, C , and Ciliberto, G. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signalling. EMBO J., 14: 1942-1951, 1995
18. Brakenhoff, J P. J., de Hon, F. D., Fontaine, V , ten Boekel, E., Schooltink, H., Rose-John, S., Heinrich, P. C., Content, J., and Aarden L. A Development of a human interleukin-6 Receptor antagonist. J. Biol. Chem., 269: 86-93, 1994.
19. Savino, R., Ciapponi, L., Lahm, A., Demartis, A., Cabibbo, A., Toniatti, C., Delmastro, P., Altamura, S , and Ciliberto, G. Rational design of a receptor superantagonists of human interleukin-6. EMBO J., 13: 5863-5870, 1994.
20. de Hon, F. D., Ehlers, M., Rose-John, S., Ebeling, S. B., Lkasse Bos, H , Aarden L. A., and Brakenhoff, J. P. J Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J. Exp. Med., 180: 2395-2400, 1994
21. Ciapponi, L., Graziani, R., Paonessa, G., Lahm, A., Ciliberto, G, and Savino, R. Definition of a composite binding site for gp130 in human interleukin-6. J Biol. Chem., 270: 31249-31254, 1995.
22. Cabibbo, A., Sporeno, E., Toniatti, C , Altamura, S , Savino, R., Paonessa, G., and Ciliberto, G. Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix. Gene (Amst), 167: 41-47, 1995.
23. Sporeno, E , Savino, R., Ciapponi, L., Paonessa, G., Cabibbo, A , Lahm, A., Pulkki, K., Sun, R-X , Toniatti, C., Klein, B., and Ciliberto, G. Human IL-6 receptor superantagonists with high potency and wide spectrum on multiple myeloma cells. Blood, 87: 4510-4519, 1996.
24. Hardin, J., Macleod, S., Grigorieva, I., Chang, R , Barlogie, B., Xiao, H , Epstein, J. Interleukin-6 prevents dexamethasone-induced myeloma cells death Blood, 84: 3063-3070, 1994.
25. Kawano, M M., Mihara, K , Huang, N., Tsujimoto, T., and Kuramoto, A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood, 85: 487-494, 1995.
26. Zhang, X., Gaillard, J. P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J. M., Bataille, R., and Klein, B Reproducible obtaining of human myeloma cell lines as a model for rumor stem cell study in human multiple myeloma. Blood, 83: 3654-3663, 1994.
27. Wagner, B. J., Hayes, T. E., Hoban, C. J. and Cochran, B. H. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J , 9: 4477-4484, 1990.
28. Sadowski, H B., and Gilman, M Z Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature (Lond.), 362: 79-83, 1993
29. Melino, G., Annichiarico-Petruzzelli, M., Piredda, L , Candi, L , Candi, E., Gentile, V., Davies, P. J A., and Piacentini, M Tissue-transglutaminase and apoptosis: sense and antisense transfection studies in human neuroblastoma cells. Mol Cell. Biol., 14: 6584-6596, 1994.
30. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ by specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992
31. L Cancer Res., 55: 2262-2265, 1995.
32. L and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth & Differ , 6: 647-653, 1995.
33. Zhong, Z., Wen, Z., and Darnell, J. E. Stat3, a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Science (Washington DC), 264: 95-98, 1994.
34. Jourdan, M , Zhang, X. G., Portier, M., Boiron, J M., Bataille, R., and Klein, B. IFN-α induced autocrine production of IL-6 in myeloma cell lines. J. Immunol., 147: 4402-4407, 1991.
35. Wegenka, U M., Lutticken, C., Buschmann, J., Yuan, J., Lottspeich, F., Muller-Esterl, W., Schindler, C., Roeb, E., Heinrich, P. C., and Horn, F. The interleukin-6-activated acute phase response factor is antigenically related to members of the signal transducer and activator of transcription (STAT) family Mol. Cell Biol , 14: 3186-3196, 1994.
36. Dhein, J., Walczak, H , Baumler, C., Debatin K. M., and Krammer, P. H. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature (Lond.), 373: 438-441, 1995
37. Westendorp, M O., Frank, R , Ochsenbauer, C., Stricker, K , Dhein, J., Walczak, H , Debatm, K. M , and Krammer, P. H. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (Lond.), 375: 497-500, 1995.